Skip to main content
Clinical Trials/NCT02113943
NCT02113943
Completed
Phase 2

Etude Comparative Monocentrique, randomisée, en Cross-over, en Double Aveugle, Contre Placebo, de l'Action du Citalopram Sur Les paramètres Cognitifs de la Motivation

Institut National de la Santé Et de la Recherche Médicale, France1 site in 1 country24 target enrollmentApril 2014

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Normal Volunteers
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Enrollment
24
Locations
1
Primary Endpoint
Reward sensitivity
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The aim of the current study is to examine the role of serotonin on the cognitive parameters of motivation. They are embedded in a conceptual framework of motivation that merges decision-making and reinforcement learning theories. Every action is conceived as path from one state to another. The different states are associated to different values (positive for rewards and negative for punishments), and the different actions to different costs (risk, effort and delay). The tasks are designed such that the sensitivity to the state and action parameters can be inferred by fitting computational models.The primary objective is to characterize the effect of Citalopram 30mg on reward sensitivity, assessed in an incentive force task, in which participants are asked to squeeze a hand grip to win monetary rewards. Secondary objectives are to characterize the effect of Citalopram 30mg on other cognitive parameters of motivation (assessed with a motivational battery that includes rating, choice and learning tasks).

Registry
clinicaltrials.gov
Start Date
April 2014
End Date
June 2014
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Man or woman, age ≥ 18 and \< 50
  • Weight between 50 kg and 90 kg.
  • No contraindication to effort
  • No evolutive pathology that could interfere with the current study signed consent
  • medical insurance ("sécurité sociale")

Exclusion Criteria

  • Age \< 18 or \> 50
  • Person under curatorship, or guardianship, or with civil rights deprivation
  • History of neurologic or psychiatric pathology
  • Presence of any psychotropic treatment
  • Chronic or actual consumption of alcohol, or psychotropic drugs
  • pregnancy, breastfeeding
  • Woman of childbearing potential without effective contraception
  • Hypersensitivity to atomoxetine or other constituents of the product
  • Pheochromocytoma
  • Narrow angle Glaucoma

Outcomes

Primary Outcomes

Reward sensitivity

Time Frame: Multiple Time Frame: 2h after placebo, 2h after Citalopram 30mg

Apathy will be assessed as the sensitivity to rewards in an incentive force task. The primary Outcome measure is the change in this parameter between the placebo condition and the Citalopram condition.

Study Sites (1)

Loading locations...

Similar Trials